Follow The Filings

LIVN Livanova PLC

Health Care, filed as LIVANOVA PLC (SHS), Equity Among managers we track Quote on Google Finance, opens in a new tab

No current holdings among managers we track for this security. See ownership history or the ownership grid, activity, or search.

Insider trades

Open-market buys and sales by LIVN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All LIVN insider trades
  • None no insider bought on the open market
  • $1M sold by 3 insiders outside a trading plan
  • $227K sold by 1 insider under 10b5-1 plans
  1. Alex Shvartsburg CFO
    Planned sale
    $227K 2,500 shares at $90.91 5.6% of stake
    Traded Nov 12 Filed Nov 13
  2. Francesco Bianchi Director
    Sale
    $273K 3,500 shares at $78.01 44% of stake
    Traded Sep 10 Filed Sep 14
  3. Brooke Story Director
    Sale
    $187K 2,300 shares at $81.42 24% of stake
    Traded Sep 4 Filed Sep 8
  4. Francesco Bianchi Director
    Sale
    $132K 1,650 shares at $79.72 17% of stake
    Traded Aug 31 Filed Sep 2
  5. Ahmet Tezel Chief Innovation Officer
    Sale
    $208K 2,675 shares at $77.74 31% of stake
    Traded Aug 11 Filed Aug 13
  6. Francesco Bianchi Director
    Sale
    $96K 1,200 shares at $80.19 11% of stake
    Traded Jun 15 Filed Jun 17
  7. Francesco Bianchi Director
    Sale
    $136K 1,800 shares at $75.75 20% of stake
    Traded May 26 Filed May 27
  8. Brooke Story Director
    Sale
    $13K 250 shares at $53.94 3.9% of stake
    Traded Nov 18, 2025 Filed Nov 19, 2025

Also filed in the last 12 months, not counted as buying or selling: 22 share withholdings for taxes, 21 option exercises, and 1 sale back to the company.

SEC filings

Recent issuer filings from EDGAR, 15 shown.

Filed Form Detail Links
SCHEDULE 13G —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
SCHEDULE 13G —
8-K 2.02,9.01
10-Q
8-K 5.07,9.01
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
DEF 14A
DEFA14A
8-K 2.02,9.01
10-K

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.15B $1.25B $1.39B
Gross profit $771.25M $870.87M $939.87M
Gross margin * 66.9% 69.5% 67.7%
Net income $17.55M $63.23M -$242.47M
Net margin * 1.5% 5.0% -17.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.988B $1.13B $1.1B
Total non-current assets * $1.44B $1.38B $1.5B
Total assets $2.43B $2.51B $2.61B
Total current liabilities $334.98M $392.12M $808.07M
Total non-current liabilities * $816.95M $794.01M $597.99M
Total equity $1.28B $1.32B $1.2B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $74.91M $183.04M $254.34M
Cash from investing -$40.33M -$48.16M -$72.91M
Cash from financing $21.48M $18.55M -$285.66M
Net change in cash $62.25M $145.68M -$88M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf